Clinical Trial Update: Study of MEDI-507 in With Steroid-Resistant Acute Graft-Versus-Host Disease [Phase 1]

View source ↗

Summary

Phase 1 study of MEDI-507 for steroid-resistant acute graft-versus-host disease in cancer patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Graft-versus-host Disease

Drugs mentioned

• MEDI-507

Snippet

Sponsor: MedImmune LLC | Conditions: Cancer, Graft-Versus-Host Disease | Phase 1 | Status: COMPLETED